AP PHarma as announced that it has received a Complete Response Letter (CRL) from the FDA regarding its New Drug...
AbbVie announced positive top-line results from SELECT-GCA, a Phase III, multicenter, randomized, double-blind, placebo-controlled study, showing upadacitinib (Rinvoq; 15 mg, once daily) in combination with a 26-week steroid taper regimen achieved its primary endpoint of sustained remission from week 12 through week 52 in adults with giant cell arteritis (GCA).
Biogen Idec has announced that results from the daclizumab high-yield process (DAC HYP) SELECT clinical trial have been published as...
AbbVie announced positive results from the ongoing Phase IIb/III SELECT-SUNRISE clinical trial showing that at 12 weeks, all doses of...
AbbVie announced new patient-reported outcomes data from the ongoing Phase III SELECT-MONOTHERAPY trial evaluating ABT 494 (upadacitinib) (15 mg and...
AbbVie announced that the New England Journal of Medicine has published 24-week results from the Phase III SELECT-PsA 1 trial evaluating Rinvoq (upadacitinib, 15 mg and 30 mg) in adults with active psoriatic arthritis who had responded inadequately or were intolerant to one or more non-biologic disease modifying anti-rheumatic drugs (DMARDs).
Objectives: To assess VTE recurrence and bleeding, with anticoagulation or not, beyond 6 months.
Novo Nordisk announced the headline results from the SELECT cardiovascular outcomes trial
AbbVie announced the publication of positive results from the pivotal Phase III SELECT-MONOTHERAPY clinical trial of ABT 494 (upadacitinib) in...